Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.

Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H.

Bone Marrow Transplant. 2004 Oct;34(7):615-9.

PMID:
15258562
2.

Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.

Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, Manson J, de Kerviler E, Briere J, Mounier N.

Cancer. 2005 Dec 15;104(12):2735-42.

3.

Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.

Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2005 Feb;11(2):129-35.

4.

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.

J Clin Oncol. 2005 Nov 1;23(31):7994-8002. Epub 2005 Oct 3.

5.

Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Seshadri T, Pintilie M, Kuruvilla J, Keating A, Tsang R, Zadeh S, Crump M.

Leuk Lymphoma. 2009 Mar;50(3):380-6. doi: 10.1080/10428190902756578.

PMID:
19347727
6.

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.

Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung H, Krishnan A, Molina A, Nademanee A, O'Donnell M, Popplewell L, Rodriguez R, Forman SJ, Bhatia S.

J Clin Oncol. 2005 Sep 20;23(27):6699-711.

7.
8.

Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.

Lee MY, Chiou TJ, Hsiao LT, Yang MH, Lin PC, Poh SB, Yen CC, Liu JH, Teng HW, Chao TC, Wang WS, Chen PM.

Ann Hematol. 2008 Apr;87(4):285-9. Epub 2007 Oct 18.

PMID:
17943285
9.

Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.

Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C.

Transfusion. 2009 Sep;49(9):1890-900. doi: 10.1111/j.1537-2995.2009.02202.x. Epub 2009 May 11.

PMID:
19453991
10.
11.

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ.

Bone Marrow Transplant. 2006 Jun;37(11):1017-22.

PMID:
16633361
12.
13.

High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study.

Mayr AJ, D√ľnser MW, Ritsch N, Pajk W, Friesenecker B, Knotzer H, Ulmer H, Wenzel V, Hasibeder WR.

Wien Klin Wochenschr. 2004 May 31;116(9-10):310-7.

PMID:
15237656
14.

Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.

Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA.

Cancer J. 2005 Sep-Oct;11(5):425-31.

PMID:
16259874
15.

The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant.

Wendland MM, Smith DC, Boucher KM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK.

Am J Clin Oncol. 2007 Apr;30(2):156-62.

PMID:
17414465
16.
17.
18.

Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study.

Mihu CN, Schaub J, Kesh S, Jakubowski A, Sepkowitz K, Pamer EG, Papanicolaou GA.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1429-33. doi: 10.1016/j.bbmt.2008.09.005.

19.

Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma.

Lenain C, Dumontet C, Gargi T, Chassagne C, Berger F, Perol D, Garnier M, Coiffier B, Blay JY.

Hematol J. 2004;5(5):403-9. Review.

PMID:
15448666
20.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators.

J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk